Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834484 | 1.00 | IDO1 (0.52) | IDO1TDO2JAK2JAK3PTK2 | |
| SCHEMBL4718908 | 0.94 | KDM4E (0.48) | IDO1TDO2GPR119CYP2C9KDM4E | |
| SCHEMBL13960438 | 0.86 | IDO1 (0.51) | IDO1TDO2JAK2JAK3PTK2 | |
| SCHEMBL2009591 | 0.85 | GRIN2B (0.40) | IDO1TDO2JAK2GPR119CYP2C9 | |
| SCHEMBL13834763 | 0.84 | IDO1 (0.55) | IDO1TDO2JAK2JAK3PTK2 | |
| SCHEMBL13834569 | 0.84 | MEN1 (0.45) | CYP2C9NAMPTMEN1KMT2A | |
| SCHEMBL2014265 | 0.84 | MEN1 (0.45) | CYP2C9NAMPTMEN1KMT2A | |
| SCHEMBL18741618 | 0.83 | MEN1 (0.53) | GPR119MEN1KMT2A | |
| SCHEMBL18741616 | 0.83 | MEN1 (0.53) | GPR119MEN1KMT2A | |
| SCHEMBL18075571 | 0.82 | IDO1 (0.49) | IDO1TDO2JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| EP-2503890-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066211-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, COASY | IDO1 2039/4885TDO2 2356/4885JAK2 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.